About BSMO

The Belgian Society of Medical Oncology unites Belgian physicians - internists specialized in the treatment of cancer.
 

Learn more about BSMO

Latest news

FDA Approves Palbociclib in Combination With Fulvestrant in Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

February 25, 2016

On February 19, 2016, the U.S. Food and Drug Administration approved palbociclib (Ibrance) in combination with fulvestrant for the treatment of women with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer with disease progression following endocrine therapy.

To read the whole article click here

Read more

News archive